Lipoic acid alleviates LPS-evoked PC12 cell damage by targeting p53 and inactivating the NF-κB pathway

Jieping Mao1# *, Hua Gao2,3#, Wen Bai4, Haibo Zeng4, Yafang Ren3, Yu Liu4 and Xinling Yang2*

1 Department of Neurology, Shenzhen Pingle Orthopedics Hospital, Shenzhen, P.R. China,
2 Department of Neurology, Second Affiliated of Xinjiang Medical University, Urumqi, P.R. China,
3 Department of Neurology, Fifth Affiliated of Xinjiang Medical University, Urumqi, P.R. China,
4 Department of Neurology, Urumqi Friendship Hospital, Urumqi, P.R. China,
# Co-first author: The two authors contributed equally to this work,
* Email: STKK0502@163.com

INTRODUCTION

Parkinson’s disease (PD) is a multifactorial degenerative disease that can cause tremor, stiffness of gait and decreased movement, thereby affecting normal life (Lotankar et al., 2017). The major pathology of PD is the loss of dopaminergic neurons in the substantia nigra (Hughes et al., 1992; Bergman and Deuschl, 2002). Several reports have proposed that the inflammatory response participates in the progression of dopaminergic neuron degeneration (McGeer and McGeer, 2008; Frank-Cannon et al., 2009). Tumor necrosis factor (TNF-α), interleukin (IL)-1β and IL-6, three critical harmful inflammatory mediators (Nagatsu and Sawada, 2005; Sawada et al., 2006), were found to exacerbate dopaminergic neuron damage (Stoll et al., 2000; More et al., 2013), resulting in chronic inflammation. Such persistent inflammation may further worsen PD. Thus, it is necessary to explore effective molecules that suppress the occurrence of inflammation in PD.

PC12 cells exhibit physiological characteristics with similar properties to dopaminergic neurons (Yagnik and Benzeroual, 2013; Zhong et al., 2015), therefore, we used PC12 cells treated with lipopolysaccharide (LPS) to simulate an in vitro model of PD.
Lipoic acid (LA), also called thioctic acid, has become a frequent component in multivitamin formulations, anti-aging supplements, and even pet food (Shay et al., 2009). Additionally, LA has been identified as a potential biological antioxidant, an antidote, and a diabetes drug (Rochette et al., 2015). LA was also shown to prevent age-related cardiovascular disease and cognitive and neuromuscular deficits, as well as being described as a regulator of diverse inflammatory pathways (Scott et al., 1994; Suh et al., 2004). Together these studies highlight the benefits of LA for humans. Moreover, it has been proposed that LA protects dopaminergic neurons in an LPS-evoked PD model (Li et al., 2015). However, the specific molecular mechanism of LA in PD has not been elucidated.

p53, as a stress response gene, has been implicated in various cell death pathways. Some reports have demonstrated that p53 dysregulation is involved in neuronal damage in neurodegenerative disease (Culmsee and Mattson, 2005). Significantly, p53 depletion was presented to be good under circumstance of neuronal damage (Keramaris et al., 2003). A previous study revealed that altering the p53 signaling pathway was essential for acupuncture-induced neuronal protection and dopaminergic neuron function in a mouse model of PD (Park et al., 2015). Moreover, p53 has been shown to be highly expressed in PD brains. Thus, inhibition of p53 expression is a valid potential method for improving PD.

Herein, we constructed an in vitro PD model by using LPS-stimulated PC12 cells and our data indicated that LA effectively reduced the LPS-induced inflammation damage of PC12 cells by targeting p53. These findings provide a theoretical basis for investigating the role of LA in PD.

METHODS

Cell culture and treatment

PC12 cells were obtained from the Shanghai Cell Bank of the Chinese Academy of Science (Shanghai, China) and were cultured in DMEM medium followed by 10% fetal bovine serum (FBS), including a 1% penicillin-streptomycin mixture. The cells were placed in a humidified incubator with 5% CO2 and 95% air at 37°C. An in vitro model of PD was established by stimulation of PC12 cells with 500 ng/mL LPS for approximately 24 h. Different concentrations of alpha-lipoic acid (LA; 50, 100, 200 μmol/mL) were applied to treat PC12 cells to detect the effect of LA in PC12 cells. Small interfering RNA p53 (si-p53) was purchased from Sango (Shanghai, China) and used to knockdown p53 expression. The si-p53 fragment was loaded into cells with Lipofectamine 2000 for transfection (Invitrogen, Carlsbad, CA, USA).

Cell viability detection

Exponentially growing PC12 cells were transplanted into 96-well plates for culture and detection. Cell viability was determined using a cell counting kit-8 (CCK-8, Beyotime, China) every 24 h, a mixture of 10 μL CCK-8 reagent and 100 μL of DMEM (excluding FBS) was added into each well, and the cells were cultured for 1.5 h under the above conditions. Finally, the optical density (OD) was observed at 450 nm wavelength.

Enzyme-linked immunosorbent assay (ELISA)

The levels of IL-1β, IL-6, TNF-α, α-syn, Nurr1 and tyrosine hydroxylase (TH) were tested using corresponding ELISA kits (Jianglaibio, China). All operations were carried out based on the manufacturer’s instructions.

Cell apoptosis detection

The apoptosis rate was assessed with a flow cytometry assay. First, the cells were seeded into six-well plates and cultured overnight. After different stimulations, the cells were gathered, rinsed with PBS and resuspended in binding buffer. Thereafter, the cells were put into a mixture with 5 μL Annexin V-FITC and 5 μL propidium iodide (PI) and cultured at approximately 25°C for 15 min away from the light. Finally, the rate of apoptosis was determined by flow cytometry within 1 h.

Cell cycle detection

First, the cells were seeded into six-well plates and cultured overnight. After different stimulations, the cells were gathered and rinsed with PBS. Then, the cells were cultured for 30 min at 37°C with RNase A solution treatment. Thereafter, 400 μL PI was loaded and the cells were cultured for 30 min at approximately 25°C. The percentage of cells in the G1, S and G2 phase was analyzed by flow cytometry.

Immunocytochemistry

Coverslips were placed on the bottom of six-well plates and cells were seeded. Afterwars, the culture
solution was removed and the plates were rinsed with PBS. Then, the cells were fixed with 4% paraformaldehyde for 12 min, permeabilized with ice-cold methanol for 2 min and incubated with anti-α-syn, anti-Nurr1 and anti-TH at 4°C for 24 h. After rinsing, the cells were incubated with secondary antibody.

**RT-qPCR**

First, total RNA was reverse transcribed into cDNA. RT-qPCR solution included 2 µL cDNA, 5 µL mixture, 0.5 µL forward/reverse primer and 2 µL nanopure water. The cycles of the amplification reaction were as follows: denaturation at 95°C for 10 s, extension at 60°C for 1 min, the reaction completed for 40 cycles. The experiment was performed in replicates. GAPDH was selected as the internal control.

**Western blotting**

The treated cells were rinsed with PBS and lysed with RIPA solution including 1 mM PMSF. The concentration of protein was detected with the BCA method. Next, 20 µg of sample was added into loading buffer and separated by 10% SDS-PAGE. After transfer, the PVDF membrane was sealed for 2 h at approximately 25°C by 5% skim milk. Thereafter, the membranes were probed with the primary antibodies against P65 NF-κB, p-P65 NF-κB, 1xBα and p-1xBα or β-actin over night at 4°C. The next day, the membranes were incubated with specific secondary antibody for 2 h at room temperature. Finally, the proteins were developed by enhanced chemiluminescence and quantified by ImageJ software.

**Statistical analyses**

All data were processed with GraphPad Prism 8.0 and SPSS 22.0 software. The differences among multiple groups were evaluated by one-way ANOVA. P<0.05 was considered statistically significant.

**RESULTS**

**LA effectively reduced toxicity, inflammation, apoptosis and cell-cycle arrest triggered by LPS in PC12 cells**

Different concentrations of LPS were applied to stimulate PC12 cells to mimic the inflammatory environment. Cell viability, tested by CCK-8 assay, was reduced by LPS (100, 200, 500, 1000 ng/mL) treatment. 500 ng/mL LPS was used for subsequent experiments due to its 50% reduction in cell viability (Fig. 1A, F_{4,10}=47.559, P<0.05). Then, different concentrations of LA were utilized to treat PC12 cells after LPS treatment. The data showed that 100 µmol/mL LA had a higher effect on PC12 cell viability than 50 and 200 µmol/mL LA under the LPS condition (Fig. 1B, F_{4,10}=24.376, P<0.05). The results from the ELISA kit revealed that the increase in IL-1β (Fig. 1C, F_{4,10}=35.578, P<0.05), IL-6 (Fig. 1D, F_{4,10}=37.442, P<0.05) and TNF-α (Fig. 1E, F_{4,10}=68.114, P<0.01) levels in LPS-induced PC12 cells was reduced by LA (50, 100, 200 µmol/mL) treatment and the efficiency of 100 and 200 µmol/mL LA was higher than that of 50 µmol/mL LA, but there was no significant difference between 100 and 200 µmol/mL LA treatment.

A flow cytometry assay was applied to detect the effect of LA on PC12 cell apoptosis and cell cycle under LPS stimulation. The increase in PC12 cell apoptosis rate triggered by LPS was suppressed by LA (50, 100, 200 µmol/mL) stimulation. Compared with 50 µmol/mL LA treatment, 100 and 200 µmol/mL LA had the same high efficiency in relieving cell apoptosis (Fig. 2A, F_{4,10}=105.822, P<0.01). Moreover, LPS-induced PC12 cell cycle arrest was relieved by LA (50, 100, 200 µmol/mL) treatment, and 100 and 200 µmol/mL LA were more efficient than 50 µmol/mL LA (Fig. 2B, F_{4,10}=10.448, P<0.01). Thus, 100 µmol/mL LA significantly alleviated PC12 cell damage induced by LPS.

**The expression of α-syn, Nurr1 and TH in LPS-induced PC12 cells was modified by LA**

Data from the immunocytochemistry and ELISA assays showed that the expression of α-syn increased, while Nurr1 and TH expression decreased, in LPS-stimulated PC12 cells. However, LA succeeded in suppressing the phenomenon. We observed that the increase in α-syn (Fig. 3A, F_{4,10}=19.956, P<0.05) and decrease in Nurr1 (Fig. 3B, F_{4,10}=12.517, P<0.05) and TH (Fig. 3C, F_{4,10}=20.386, P<0.05) in LPS-stimulated PC12 cells was inhibited by LA (50, 100, 200 µmol/mL) treatment. Moreover, 100 µmol/mL LA had the highest efficiency in the regulation of α-syn, Nurr1 and TH expression compared with 50 and 200 µmol/mL LA.

p53 was confirmed as a target of LA and jointly regulated PC12 cell damage with LA.

Based on the importance of the p53 gene in PD and predictions generated by the Comparative Toxicog-
In the CTD website, we preliminarily speculated that p53 may be a potential target of LA. Importantly, we observed that p53, highly expressed in LPS-induced PC12 cells, was suppressed by LA (Fig. 4A, $F_{2,6}=8.386, P<0.05$) and that si-p53 could significantly reduce p53 expression (Fig. 4B, $F_{2,6}=36.692, P<0.01$). We also discovered that knockdown of p53 reduced the increased levels of IL-1β, IL-6 and TNF-α triggered by LPS in PC12 cells. Moreover, the depletion of p53 enhanced the apoptotic rate of PC12 cells (Fig. 5A, $F_{4,10}=185.406, P<0.01$) induced by LPS and inhibited the cell cycle arrest (Fig. 5B, $F_{4,10}=23.965, P<0.01$). However, the above results were also achieved after LA and si-p53 combination treatment (Fig. 5A-B). The increase in α-syn (Fig. 6A, $F_{4,10}=13.537, P<0.05$; 6D, $F_{4,10}=18.028, P<0.05$) and decrease in Nur1 (Fig. 6B, $F_{4,10}=18.084, P<0.05$; 6E, $F_{4,10}=10.555, P<0.05$) and TH (Fig. 6C, $F_{4,10}=12.289, P<0.05$; 6F, $F_{4,10}=14.670, P<0.05$) in LPS-triggered PC12 cells were inhibited after p53 depletion. Moreover, these changes were more significant when LA and si-p53 were applied together. Together, these data illustrate that protective effects were achieved with LA in PC12 cells by targeting p53.

The NF-κB pathway was found to be involved in the protective effect of LA/p53 in PC12 cells

The NF-κB signaling pathway has been shown to be activated in PD, thereby increasing the levels of TNF-α, IL-1β and IL-6 (Han et al., 2016). Moreover, LA is also widely known as an inhibitor of NF-κB (Packer et al., 1995). Therefore, we used the western blotting to investigate the effect of LA/p53 on the NF-κB signaling pathway. The results revealed that the levels of p-P65 NF-κB and p-IκBα were reduced after either LA or si-p53 treatment. In addition, compared with LA or si-p53 treatment alone, co-treatment with LA and si-p53 reduced the expression of p-P65 NF-κB (Fig. 7A, $F_{3,8}=32.681, P<0.05$) and p-IκBα (Fig. 7A, $F_{3,8}=24.078, P<0.05$) even more significantly. Therefore, the mitigative effect of LA on LPS-induced PC12 cell damage was achieved by targeting p53 and inactivating the NF-κB signaling pathway.
Fig. 2. The increased apoptosis rate and G1 phase arrest of PC12 cells triggered by LPS were inhibited by LA stimulation. (A) LPS induced an increase in PC12 cell apoptosis, which was suppressed by different concentrations of LA treatment. (B) LPS induced PC12 cell arrest in G1 phase, while treatment with different concentrations of LA inhibited PC12 cell cycle arrest. **P<0.01 vs. control; ***P<0.01 vs. LPS; ###P<0.01 vs. LPS+50 µmol/mL LA.
Fig. 3. The increased α-syn and decreased Nurr1 and TH in LPS-induced PC12 cells were suppressed after LA treatment. (A and D) LA treatment suppressed the increase of α-syn caused by LPS in PC12 cells. In PC12 cells, the decrease of Nurr1 (B and E) and TH (C and F) caused by LPS were suppressed by LA stimulation. **P<0.01 vs. control; *P<0.05, **P<0.01 vs. LPS; †P<0.05, ††P<0.01 vs. LPS+50 µmol/mL LA.
Fig. 4. p53, highly expressed in LPS-induced PC12 cells, was suppressed by LA treatment. (A) RT-qPCR was used to detect p53 expression in PC12 cells after LPS or LPS+LA treatment. (B) si-p53 clearly reduced p53 mRNA expression. (C-E) Knockdown of p53 strengthened the inhibitory effects of LA on IL-1β, IL-6 and TNF-α expression. **P<0.01 vs. control; *P<0.05, **P<0.01 vs. LPS; †P<0.05 vs. LPS+100 µmol/mL LA; ‡P<0.05, ‡‡P<0.01 vs. LPS+si-p53.
Fig. 5. LA attenuated the apoptosis and eliminated cell cycle arrest in LPS-induced PC12 cells by targeting p53. (A) Flow cytometry was used to detect the effect of LA and p53 on PC12 cells apoptosis under the LPS condition. (B) The function of LA and p53 on PC12 cell cycle was measured by flow cytometry under LPS stimulation. **P<0.01 vs. control; ###P<0.01 vs. LPS; ##P<0.01 vs. LPS+100 µmol/mL LA; @@P<0.01 vs. LPS+si-p53.
Fig. 6. The effects of LA on α-syn, Nurr1 and TH levels were strengthened by p53 depletion. (A and D) LA suppressed the increasing trend of α-syn in LPS-induced PC12 cells, and depletion of p53 enhanced the inhibitory effect of LA on α-syn level. (B, C, E and F) The decreased trends of Nurr1 and TH in LPS-induced PC12 cells were inhibited by LA treatment, which were strengthened by p53 knockdown. **P<0.01 vs. control; *P<0.05, **P<0.01 vs. LPS; †P<0.05, ††P<0.01 vs. LPS+100 µmol/mL LA; $P<0.05, $$P<0.01 vs. LPS+si-p53.
Neuroinflammation is one of the important pathogeneses of neurodegenerative diseases including PD (Hill-Burns et al., 2011). The levels of the pro-inflammatory mediators TNF-α, IL-1 and IL-6 in the brain of PD patients were found to be elevated (Reale et al., 2009). Therefore, inflammation might be a basic process leading to the death of neurons in PD, and anti-inflammatory treatment may provide a specific neuroprotective therapy for PD. Herein, PC12 cells exposed to LPS were used to construct an in vitro module of PD and it was found that LA can alleviate LPS damage to PC12 cells.

LA has been reported to prevent hydrogen peroxide-triggered neuronal damage, protect neurons from neurotoxicity and decrease oxidative damage (Li et al., 2015). Moreover, LA has the ability to suppress LPS-triggered inflammatory processes (Suh et al., 2015). Additionally, a study by Li and colleagues (2015) revealed that LA treatment improved motor dysfunction and suppressed the expression of pro-inflammatory molecules in M1 microglia. However, our study not only revealed an effect of LA on inflammatory factors and α-syn but also effects on apoptosis, cell cycle, Nurr1 and TH. Moreover, we also found that LA suppressed damage in PC12 cells exposed to LPS by targeting p53.

P53 has an important role in the death of neurons in many neurodegenerative diseases. The evidence comes primarily from the fact that p53 levels are found to be greatly increased in affected neurons in both in vivo and in vitro experimental models (Dai et al., 2016). Moreover, it has been proposed that p53 overexpression regulates apoptosis, resulting in neuronal loss in the substantia nigra pars compacta, leading to PD (Fauvel et al., 2001). In our study, we observed that p53 was highly expressed in LPS-triggered PC12 cells, while LA stimulation clearly reduced p53 expression. Moreover, knockdown of p53 suppressed the release of TNF-α, IL-1β and IL-6, inhibited cell apoptosis and eliminated cell cycle arrest in LPS-induced PC12 cells, which suggested that p53 played a promoting role in LPS-induced PC12 cell injury.

Previous studies have reported that α-syn aggregates have been found in the central nervous system in PD (Kim et al., 2019). It is well documented that Nurr1 plays an important role in the midbrain dopaminergic neuronal development, differentiation and survival. It has also been proposed that the decreases in Nurr1 are related to PD, and TH expression has been found to decrease in the substantia nigra pars compacta region with the progression of PD (Kordower et al., 2013; Dong et al., 2016). In our study, we observed that the level of α-syn was increased in LPS-induced PC12 cells, while Nurr1 and TH were reduced. However, after treatment with LA or si-p53, these phenomena were reversed, indicating that LA or si-p53 alleviated PC12 cell damage by regulating the levels of α-syn, Nurr1 and TH.
The NF-κB signaling pathway was found to be activated in PD, thereby increasing the levels of TNF-α, IL-1β and IL-6 (Han et al., 2016). Moreover, LA is also widely known as an inhibitor of NF-κB (Packer et al., 1995). Interestingly, we found that the levels of p-P65 NF-κB and p-IκBα were significantly reduced after LA treatment when PC12 cells were exposed to LPS. Moreover, knockdown of p53 strengthened the inhibitory effect of LA on p-P65 NF-κB and p-IκBα expression. Therefore, our data suggests that the LA exerts an effect on PC12 cells exposed to LPS partly through targeting p53 and mediating the NF-κB pathway.

CONCLUSIONS

Taken together, our results revealed that LA can alleviate the inflammatory response, apoptosis and cell cycle arrest of PC12 cells induced by LPS by targeting p53 and inactivating NF-κB pathway. These findings provide a theoretical basis for further investigation of the mechanism of LA in neuroinflammation.

ACKNOWLEDGMENTS

This study was funded by the Natural Science Foundation of Xinjiang Uygur Autonomous Region.

REFERENCES

Bergman H, Deuschl G (2002) Pathophysiology of Parkinson’s disease: from clinical neurology to basic neuroscience and back. Mov Disord 17: 528–40.

Culmsee C, Mattson MP (2005) p53 in neuronal apoptosis. Biochem Biophys Res Commun 331: 761–777.

Dai CQ, Luo TT, Luo SC, Wang JQ, Wang SM, Bai YH, Yang YL, Wang YY (2016) p53 and mitochondrial dysfunction: novel insight of neurodegenerative diseases. J Bioenerg Biomembr 48: 337–347.

Dong J, Li S, Mo JL, Cai HB, Le WD (2016) Nurr1-based therapies for Parkinson’s disease. CNS Neurosci Ther 22: 351–359.

Fauvel H, Marchetti P, Choppin P, Formstecher P, Nèveře R (2001) Differential effects of caspase inhibitors on endotoxin-induced myocardial dysfunction and heart apoptosis. Am J Physiol Heart Circ 280: H1608–1614.

Frank-Cannon TC, Alto LT, McAlpine FE, Tansey MG (2009) Does neuroinflammation fan the flame in neurodegenerative diseases? Mol Neurodegener 4: 447.

Han MH, Lee WS, Nagappan A, Hong SH, Jung JH, Park C, Kim HJ, Kim GY, Kim G, Jung JM, Ryu CH, Shin SC, Hong SC, Choi YH (2016) Flavonoids isolated from flowers of Loniceria japonica Thumb. Inhibit inflammatory responses in BV2 microglial cells by suppressing TNF-α and IL-1β through PI3K/Akt/NF-kb signaling pathways. Phytother Res 30: 1824–1832.

Hill-Burns EM, Factor SA, Zabetian CP, Thomson G, Payami H (2011) Evidence for more than one Parkinson’s disease-associated variant within the HLA region. PloS One 6: e27109.

Hughes AJ, Daniel SE, Kilford L, Lees AJ (1992) Accuracy of clinical diagnosis of idiopathic Parkinson’s disease: a clinico-pathological study of 100 cases. J Neurol Neurosurg Psychiatry 55: 181–184.

Keramaris E, Hirao A, Slack RS, Mak TW, Park DS (2003) Ataxia telangiectasia-mutated protein can regulate p53 and neuronal death independent of Chk2 in response to DNA damage. J Biol Chem 278: 37782–37789.

Kim S, Kwon SH, Kim TI, Panicker N, Karuppagounder SS, Lee S, Lee JH, Kim WR, Kook M, Foss CA, Shen C, Lee H, Kulkarni S, Pasricha PJ, Lee G, Pomper MG, Dawson VL, Dawson TM, Ko HS (2019) Transneuronal propagation of pathologic α-synuclein from the gut to the brain models Parkinson’s disease. Neuron 103: 627–641.e7.

Kordower JH, Olanow CW, Dodhya HB, Chu Y, Beach TG, Adler CH, Halliday GM, Bartus RT (2013) Disease duration and the integrity of the nigrostriatal system in Parkinson’s disease. Brain 136: 2419–2431.

Li YH, Ge Q, Yu JZ, Liu CY, Feng L, Chai Z, Wang Q, Zhang HZ, Zhang GX, Xiao BG, Ma CG (2015) Lipoic acid protects dopaminergic neurons in LPS-induced Parkinson’s disease model. Metab Brain Dis 30: 1217–1226.

Lotankar S, Prabhavalkar KS, Bhatt DL, Lak (2017) Biomarkers for Parkinson’s disease: recent advancement. Neurosci Bull 33: 585–597.

McGeer PL, McGeer EG (2008) Glial reactions in Parkinson’s disease. Mov Disord 23: 477–483.

More SV, Kumar H, Kim IS, Song SY, Choi DK (2013) Cellular and molecular mediators of neuroinflammation in the pathogenesis of Parkinson’s disease. Mediators Inflamm 2013: 952375.

Nagatsu T, Sawada M (2005) Inflammatory process in Parkinson’s disease: role for cytokines. Curr Pharm Des 11: 999–1016.

Packer L, Witt EH, Tritschler HJ (1995) α-Lipoic acid as a biological antioxidant. Free Radic Biol Med 19: 227–250.

Park JY, Choi H, Baek S, Jang J, Lee A, Jeon S, Kim J, Park HJ (2015) p53 signaling mediates acupuncture-induced neuroprotection in Parkinson’s disease. Biochem Biophys Res Commun 460: 772–779.

Reale M, Greig NH, Kamal MA (2009) Peripheral chemo-cytokine profiles in Alzheimer’s and Parkinson’s diseases. Mini Rev Med Chem 9: 1229–1241.

Rochette L, Ghibu S, Muresan A, Vergely C (2015) Alpha-lipoic acid: molecular mechanisms and therapeutic potential in diabetes. Can J Physiol Pharmacol 93: 1021–1027.

Sawada M, Imamura K, Nagatsu T (2006) Role of cytokines in inflammatory process in Parkinson’s disease. J Neural Transm Suppl 2006: 373–381.

Scott BC, Aruoma OI, Evans P, O’Neill C, Van der Vliet A, Cross CE, Stoll G, Jander S, Schroeter M (2000) Cytokines in CNS disorders: neurotoxicity versus neuroprotection. J Neural Transm Suppl 59: 81–89.

Shay KP, Moreau RF, Smith EJ, Smith AR, Hagen TM (2009) Alpha-lipoic acid as a dietary supplement: molecular mechanisms and therapeutic potential. Biochim Biophys Acta 1790: 1149–1160.

Stoll G, Jander S, Schroeter M (2000) Cytokines in CNS disorders: neurotoxicity versus neuroprotection. J Neural Transm Suppl 59: 81–89.

Suh JH, Shenvi SV, Dixon BM, Liu H, Jaiswal AK, Liu RM, Hagen TM (2004) Decline in transcriptional activity of Nrfl2 causes age-related loss of glutathione synthesis, which is reversible with lipoic acid. PNAS 101: 3381–3386.

Suh SH, Lee KE, Kim JJ, Kim O, Kim CS, Choi JS, Choi HJ, Bae EH, Ma SK, Lee JU, Kim SW (2015) Alpha-lipoic acid attenuates lipopolysaccharide-induced kidney injury. Clin Exp Nephrol 19: 82–91.

Yagnik RM, Benzeroural KE (2013) TGCycle prevents LPS-induced release of pro-inflammatory and apoptotic mediators in neuronal cells. Toxicol In Vitro 27: 686–693.

Zhong J, Fan S, Yan Z, Xiao S, Fan L, Chen C, Zhong S, Liu L, Liu J (2015) Effects of Nogo-A silencing on TNF-α and IL-6 secretion and TH down-regulation in lipopolysaccharide-stimulated PC12 cells. Biomed Res Int 2015: 817914.